Neulasta Biosimilar: Smooth Patent Dance, Stumble On Launch Notification
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen patent infringement suit follows information exchange with Apotex; Federal Circuit’s ruling on commercial notification to be tested.
You may also be interested in...
Biosimilar Barricade Breached: Amgen Manufacturing Patents Ruled Not Infringed
Apotex's Neulasta and Neupogen biosimilars do not infringe Amgen's patent, showing sponsors can get around innovator's manufacturing process patents.
Biosimilar Barricade Breached: Amgen Manufacturing Patents Ruled Not Infringed
Apotex's Neulasta and Neupogen biosimilars do not infringe Amgen's patent, showing sponsors can get around innovator's manufacturing process patents.
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
A look at the status of suits involving Remicade, Neulasta, Epogen and Enbrel proposed biosimilars; Humira patents are being challenged in inter partes review proceedings rather than district court.